Treatment of medulloblastoma with a modified measles virus

Neuro-Oncology

Volumn 12, Issue 10, 2010, Pages 1034-1042

  Studebaker, Adam W ^a   Kreofsky, Cole R ^b   Pierson, Christopher R ^a   Russell, Stephen J ^c   Galanis, Evanthia ^c   Raffel, Corey ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bioluminescence; Measles virus; Medulloblastoma; Oncolytic virus

Indexed keywords

GREEN FLUORESCENT PROTEIN; MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; MV GFP VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEASLES VIRUS; MEDULLOBLASTOMA; MOUSE; NONHUMAN; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIGENS, CD46; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SEPARATION; CEREBELLAR NEOPLASMS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MEASLES VIRUS; MEDULLOBLASTOMA; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958461551     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq057     Document Type: Article

References (30)

1. Bleyer WA. The impact in the United States and the world of central nervous system cancer during childhood. In: Packer RJ, Bleyer WA, Pochedly C, eds. Pediatric Neuro-oncology New Trends in Clinical Research. Vol. 3. Philadelphia, PA: Harwood Academic Publishers; 1992:1-7.
2. Humphreys R. Posterior cranial fossa brain tumors in children. In: Youmans JR, ed. Neurological Surgery. Philadelphia, PA: WB Saunders; 1982:2733-2752.
3. Allen JC, Bloom J, Ertel I, et al. Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. Semin Oncol. 1986;13:110-122.
4. Hughes EN, Shillito J, Sallan SE, et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer. 1988;61:1992-1998.
5. Packer RJ, Sutton LN, Atkins TE, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg. 1989;70:707-713.
6. Packer RJ, Sutton LN, Goldwein JW, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg. 1991;74:433-440.
7. Galanis E, Bateman A, Johnson K, et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001;12:811-821.
8. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirusmediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508-2518.
9. Wild TF, Malvoisin E, Buckland R. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J Gen Virol. 1991;72:439-442.
10. Tatsuo H, Ono N, Tanaka K, et al. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406:893-897.
11. Dorig RE, Marcil A, Chopra A, et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 1993;75: 295-305.
12. Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67:6025-6032.
13. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol. 1999;36:929-939.
14. Cutts FT, Markowitz LE. Successes and failures in measles control. J Infect Dis. 1994;170(suppl.):S32-S41.
15. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 2001;97:3746-3754.
16. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98: 2002-2007.
17. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003;63:2462-2469.
18. Peng KW, TenEyck CJ, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656-4662.
19. Duprex WP, McQuaid S, Hangartner L, et al. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol. 1999;73: 9568-9575.
20. Albrecht P, Shabo AL, Burns GR, et al. Experimental measles encephalitis in normal and cyclophosphamide-treated rhesus monkeys. J Infect Dis. 1972;126:154-161.
21. Buynak EBPH, Creamer VMD, Goldner H, Hilleman MR. Differentiation of virulent from avirulent measles strains. Am J Dis Child. 1962;103:460-473.
22. Myers R, Harvey M, Kaufmann TJ, et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Hum Gene Ther. 2008;19:690-698.
23. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006;66:11840-11850.
24. Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther. 2007;15:677-686.
25. Raffel C, Thomas GA, Tishler DM, et al. Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumors. Neurosurgery. 1993;33:301-305. discussion 305-306.
26. Raffel C, Ueki K, Harsh GRT, et al. The multiple tumor suppressor 1/ cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. Neurosurgery. 1995;36:971-974. discussion 974-975.
27. Raffel C. Medulloblastoma: molecular genetics and animal models. Neoplasia. 2004;6:310-322.
28. Lun XQ, Zhou H, Alain T, et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 2007;67:8818-8827.
29. Feldman S, Gigliotti F, Bockhold C, Naegele R. Measles and rubella antibody status in previously vaccinated children with cancer. Med Pediatr Oncol. 1988;16:308-311.
30. Mader EK, Maeyama T, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009;15:7246-7255.